News archive
Showing 746 results
September 2020
-
Story Education and Awareness
Day of Reflection at Novartis
On this Day of Reflection, Novartis associates are thinking and talking about what it means to be part of a truly diverse and inclusive organization.
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice Commitment to include… -
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media Release
Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis
Subgroup post hoc analysis of EXPAND reported that Mayzent reduced the risk of cognitive worsening and improved the chance of cognitive improvement at 6 months versus placebo in patients with… -
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and prolonged time to…
August 2020
-
Media Release
Novartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEF
PARALLAX met one of its co-primary endpoints, showing a significant reduction in NT-proBNP with Entresto (sacubitril/valsartan) compared to individualized medical therapy (IMT) at 12 weeks1; no… -
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164… -
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
-
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
Podcast to feature 1:1 interviews conducted by Lauper with patients and advocates to address the impact psoriasis (PsO) can have on day-to-day life Guests to include real patient advocates and… -
Media Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis